4-antigen Staphylococcus aureus vaccine - Pfizer

Drug Profile

4-antigen Staphylococcus aureus vaccine - Pfizer

Alternative Names: PF-06290510; PF-6290510; Quadrivan; SA4Ag

Latest Information Update: 19 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Staphylococcal infections

Most Recent Events

  • 01 Sep 2016 Pfizer completes a phase II trial in Staphylococcal infections (Prevention) in Japan (IM) (NCT02492958)
  • 07 Jul 2015 Phase-II clinical trials in Staphylococcal infections (Prevention) in Germany (IM)
  • 07 Jul 2015 Pfizer initiates the phase IIb STRIVE trial for Staphylococcal infections (Prevention) in USA (NCT02388165)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top